

## **KURZPROTOKOLL PADI**

<b>Öffentlicher Titel</b>	Prävention von allergischen Erkrankungen bei Säuglingen
<b>Wissenschaftl. Titel</b>	The effect of low protein, extensively hydrolyzed infant formula on allergy prevention in at-risk infants up to 1 year of age: a randomized, double-blind, controlled intervention study and the long-term effect on allergy prevention of early nutrition given in the first 120 days of life in at-risk infants until the child is 6 years of age
<b>Kurztitel</b>	PADI
<b>Studienart</b>	multizentrisch, prospektiv, randomisiert, doppelblind, dreiarmlig
<b>Studienphase</b>	nicht zutreffend
<b>Erkrankung</b>	Kinder: Allergien: Nahrungsmittelallergien
<b>Einschlusskriterien</b>	<ul style="list-style-type: none"><li>- Age at enrollment: <math>\leq</math> 56 days of life</li><li>- Healthy term-born male and female infants (gestational Age <math>\geq</math> 37+0, singleton birth)</li><li>- Birth weight <math>\geq</math> 2500 g and <math>\leq</math> 4500 g</li><li>- At risk of developing atopic diseases</li><li>- Free of atopy symptoms at Screening and at any time before randomization</li><li>- Feeding regimen at any time before Screening (V1) and Baseline (V2, infants who will receive Interventional Product (IP)): no infant formula feeding and solid foods allowed (in order to exclude prior sensitization) except amino acid formula (e.g. Neocate Infant), maltodextrin or glucose solution/gel; breastfeeding allowed</li><li>- Subject's parents/caregivers willing to comply with the feeding regimen during the intervention period. Subject's parents/caregivers will decide which feeding regimen will be used (IP or breast milk): A) IP regimen (intervention or control group): only IP and breast milk until at least 120 days of life B) breastfeeding regimen (reference group): exclusively breast milk until at least 120 days of life C) No other infant formulas or solid foods are allowed</li><li>- Written informed consent</li></ul>
<b>Ausschlusskriterien</b>	<ul style="list-style-type: none"><li>- Multiple births</li><li>- Premature delivery (gestational age <math>\leq</math> 36+6)</li><li>- Neonatal illnesses that might have an impact on allergy development (based on Investigator's decision)</li><li>- Significant congenital abnormalities</li><li>- Participation in another clinical study with an IP or study method that would influence the outcome of this study</li><li>- Reason to presume that the subject's parents/caregivers are unable to meet study plan requirements.</li></ul>
<b>Alter</b>	> 2 Monate
<b>Sponsor</b>	HIPP GmbH Co Vertrieb KG
<b>Registrierung in anderen Studienregistern</b>	ClinicalTrials.gov NCT03489733 (primäres Register)